They say they’re fine, but their rheumatic disease says otherwise

Choose a disease state for more information:

Rheumatoid arthritis (RA)

Rheumatoid arthritis (RA)

Nearly 1 in 3 patients with RA is not adequately controlled by bDMARD therapy after 1 year.1*

Find tools and resources to help patients with RA.

Ankylosing spondylitis (AS)

Ankylosing spondylitis (AS)

3 of 4 patients with AS did not achieve ASDAS low disease activity after 6 months on a bDMARD.2†

Find tools and resources to help patients with AS.

*From a real-world study of 6,209 patients with RA collected from the Corrona registry from 2002 to 2011.1
From a real-world study of 130 patients with AS collected from the CorEvitas PsA/SpA registry from March 2013 to March 2021.2

bDMARD=biological disease-modifying antirheumatic drug; PsA=psoriatic arthritis; SpA=spondyloarthritis.

References: 1. Strand V, Miller P, Williams SA, Saunders K, Grant S, Kremer J. Discontinuation of biologic therapy in rheumatoid arthritis: analysis from the Corrona RA Registry. Rheumatol Ther. 2017;4(2):489-502. doi:10.1007/s40744-017-0078-y 2. Mease P, McLean R, Blachley T, et al. Impact of achieving ASDAS LDA on disease activity and patient-reported outcome measures among patients with ankylosing spondylitis treated with biologic DMARDs. Abstract presented at: ACR Convergence; November 5-9, 2021.